Literature DB >> 21078242

Frequency and characteristic features of portal hypertensive gastropathy in patients with viral cirrhosis.

Shahid Ahmed1, Khalid Mumtaz, Umair Syed Ahmed, Hasnain Ali Shah, Shahab Abid, Saeed Hamid, Wasim Jafri.   

Abstract

OBJECTIVE: To determine the frequency and specific characteristic features of portal hypertensive gastropathy (PHG) in cirrhosis due to viral etiology. STUDY
DESIGN: Cross-sectional descriptive study. PLACE AND DURATION OF STUDY: The Aga Khan University Hospital, Karachi, from June 2006 till June 2008.
METHODOLOGY: Patients with hepatitis B and C cirrhosis were included who underwent screening esophago-gastroduodenoscopy (EGD) for varices. Baveno III consensus statement was used for diagnosing PHG on endoscopy and divided them into two subgroups i.e. mild and severe. Data related to platelet/spleen ratio, MELD score and Child Turcotte Pugh (CTP) score indicating severity of cirrhosis were recorded in all patients. Findings were compared by using independent sample t-test.
RESULTS: Out of 360 patients who underwent screening EGD, 226 (62.8%) were males. Two hundred and eighty one (78%) had hepatitis C while 79 (22%) suffered from hepatitis B related cirrhosis. Three hundred patients (83.3%) had PHG while 71 (24%) had severe PHG. Higher proportion of esophageal varices (89.7%) was present among those who had PHG (p < 0.001). On univariate analysis lower platelet counts (117±55 vs. 167±90; p < 0.001), increased spleen size (14.1±2.9 cm vs. 12±2.4cm; p < 0.001) were found in PHG patients as compared to those without it. Similarly, lower platelet/spleen ratio was noted in patients with severe PHG (916±400 vs. 1477±899; p < 0.001). Furthermore, on multivariate analysis CTP score > 8 MELD score > 12 and platelets/spleen ratio < 900 were significantly associated factors with severe PHG.
CONCLUSION: Frequency of PHG was 83% while severe PHG was seen in 24% cases of viral hepatic cirrhosis. MELD score > 12, CTP score ³ 8 and platelets/spleen ratio < 900 were significant factors of severe PHG.

Entities:  

Mesh:

Year:  2010        PMID: 21078242     DOI: 11.2010/JCPSP.714718

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  6 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

2.  Noninvasive Clinical Predictors of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis.

Authors:  Rajesh Mandhwani; Farina M Hanif; Muhammad Manzoor Ul Haque; Rajesh Kumar Wadhwa; Nasir Hassan Luck; Muhammad Mubarak
Journal:  J Transl Int Med       Date:  2017-09-30

3.  Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy.

Authors:  Muhammad Y Sheikh; Rahim Raoufi; Pradeep R Atla; Muhammad Riaz; Chad Oberer; Michael J Moffett
Journal:  Saudi J Gastroenterol       Date:  2012 Jul-Aug       Impact factor: 2.485

4.  Prevalence of Portal Hypertensive Gastropathy in Chronic Liver Disease and Correlation with the Severity of Liver disease.

Authors:  Pratap S Tiwari; Sudhamshu Kc; Dilip Sharma; Mukesh S Paudel; Amrendra Mandal
Journal:  Cureus       Date:  2019-08-21

5.  Accuracy of noninvasive tests in the prediction of portal hypertensive gastropathy in Egyptian patients with cirrhosis.

Authors:  Ibrahim F Amer; Eslam M El Shennawy; Hassan El Batea; Mohammed Hussien Ahmed; Shimaa El Sharawy; Aya M Mahros
Journal:  JGH Open       Date:  2021-01-18

6.  RLLB/Alb ratio: a promising noninvasive diagnostic marker in assessing esophageal varices in cirrhotic patients.

Authors:  Md Faisal Fahad Chowdhury; Ashekul Islam; Pulak Kanti Palit; Md Mozibullah; Md Sohel; Mst Mahmuda Khatun; Mohammed Mehadi Hassan Chowdhury; Mohammod Johirul Islam; Joyonti Datta; Suman Dhar; Pradip Kumar Nath; Sabuj Kanti Nath
Journal:  J Clin Lab Anal       Date:  2022-07-08       Impact factor: 3.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.